RT Journal Article
T1 Primary renal lymphoma: long-term results of two patients treated with a chemotherapy + rituximab protocol.
A1 Vázquez-Alonso, F
A1 Puche-Sanz, I
A1 Sánchez-Ramos, C
A1 Flores-Martín, J
A1 Vicente-Prados, J
A1 Cózar-Olmo, J M
K1 Linfoma
K1 Antineoplastic Agents
K1 rituximab
K1 Antineoplásicos
K1 Anticuerpos Monoclonales
K1 Ciclofosfamida
K1 Doxorrubicina
K1 Vincristina
K1 Prednisolona
K1 R-CHOP protocol
K1 Neoplasias Renales
AB Primary renal lymphoma (PRL) is a rare disease of which the etiology and pathogenesis remain controversial, and there is currently no standard treatment for it. We present the results of a long-term followup of two patients who were diagnosed with PRL and treated with cyclophosphamide, adriamycin, vincristine, prednisolone and rituximab (CHOP + R) regimen. Both patients reached a complete response, and there is no evidence of recurrence after 4.5- and 5-year followup periods. Based on our experience and other recently published studies, we recommend the combination of CHOP + rituximab as the elective treatment for this disease. To our knowledge, this is the longest followup period with a complete response that has been reported with this modality of treatment.
PB Hindawi Publishing Corporation
YR 2012
FD 2012-08-22
LK http://hdl.handle.net/10668/807
UL http://hdl.handle.net/10668/807
LA en
NO Vázquez-Alonso F, Puche-Sanz I, Sánchez-Ramos C, Flores-Martín J, Vicente-Prados J, Cózar-Olmo JM. Primary renal lymphoma: long-term results of two patients treated with a chemotherapy + rituximab protocol. Case Rep Oncol Med; 2012:726424
NO Journal Article;
DS RISalud
RD Apr 17, 2025